Home › Glioblastoma › NCT06090903
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Exploration Into the Association Between Decorin (DCN) Expression and MR Phenotypes in GBM
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients \> 18 years of age * Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines Exclusion Criteria: * Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker or metal in the body) * Patients \< 18 years of age
About the study
This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.
What is being tested
- Biospecimen Collection (procedure)
- Magnetic Resonance Imaging (procedure)
- Medical Chart Review (other)
Sponsor: Jonsson Comprehensive Cancer Center · Participants: 50 · Started: Apr 14, 2022
Contact the study team
Official record on ClinicalTrials.gov — NCT06090903
Locations in the U.S.
| California | UCLA / Jonsson Comprehensive Cancer Center, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.